These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patient drug safety requires P and T attention to these guidelines. Myers RS Mod Hosp; 1968 Nov; 111(5):104 passim. PubMed ID: 5712126 [No Abstract] [Full Text] [Related]
3. The drug spotlight program. Aagaard GN Ann Intern Med; 1973 Apr; 78(4):603-5. PubMed ID: 4694045 [No Abstract] [Full Text] [Related]
4. [Guidelines to the current drug therapy of hypertension. (Amendment to the 1988 decision of the Committee on Hypertension of the National Health Council)]. Török E Orv Hetil; 1989 Dec; 130(49):2645-6. PubMed ID: 2601951 [No Abstract] [Full Text] [Related]
5. Role of drug and therapeutics committee towards drug safety--experiences from western Nepal. Palaian S; Mishra P Kathmandu Univ Med J (KUMJ); 2005; 3(1):79-80. PubMed ID: 16401950 [No Abstract] [Full Text] [Related]
6. [Work of the committee on drug side effects]. Naes K Tidsskr Nor Laegeforen; 1975 Aug; 95(22):1237-8. PubMed ID: 1162664 [No Abstract] [Full Text] [Related]
7. [Drug committee: committee is going to bring about a more knowledgeable attitude to the selection of drugs]. Hagelsten JO Sygeplejersken; 1978 Mar; 78(12):4-7, 20. PubMed ID: 247708 [No Abstract] [Full Text] [Related]
8. Adverse drug reactions and the P & T committee. Lipman AG Hosp Formul; 1980 Jul; 15(7):580. PubMed ID: 10247654 [No Abstract] [Full Text] [Related]
9. [Criteria for choice of preparations in a drug committee]. Lunde PK Tidsskr Nor Laegeforen; 1975 Jan; 95(1):37-40. PubMed ID: 1111161 [No Abstract] [Full Text] [Related]
10. Promoting rational drug use through the ASHP Commission on Therapeutics. Witmer DR Am J Hosp Pharm; 1994 Jun; 51(12):1536. PubMed ID: 8092154 [No Abstract] [Full Text] [Related]
11. [Local reporting of adverse effects--an experimental work at the main hospital]. Hallberg L; Lundborg P Lakartidningen; 1974 May; 71(19):1916-7. PubMed ID: 4133506 [No Abstract] [Full Text] [Related]
12. [Pharmacy committees and the prescription of drugs]. Boréus LO Lakartidningen; 1969 Jun; 66():Suppl II:44+. PubMed ID: 5384122 [No Abstract] [Full Text] [Related]
13. [Drug supply report and expert pronouncement]. Rosén A Nord Med; 1970 Sep; 84(39):1249. PubMed ID: 5469312 [No Abstract] [Full Text] [Related]
14. The Drug Spotlight Program. Aagaard GN J Assoc Hosp Med Educ; 1978; 1st Quarter():58-60. PubMed ID: 10307276 [No Abstract] [Full Text] [Related]
15. [Control of adverse drug reaction in a hospital environment]. Honorato J; Giráldez J; Mart'i Mass'o R; Fos D; Velasco JL; S'anchez H Rev Med Univ Navarra; 1976; 20():209-11. PubMed ID: 1019512 [No Abstract] [Full Text] [Related]
16. The goals and functions of a P & T committee. Sudds TW; Williams RR Hosp Formul; 1985 Nov; 20(11):1163-5, 1171, 1174. PubMed ID: 10274572 [TBL] [Abstract][Full Text] [Related]
17. Age: a growing P & T concern. Lipman AG Hosp Formul; 1983 May; 18(5):475. PubMed ID: 10260197 [No Abstract] [Full Text] [Related]
18. [Is the present concept of commissions for expedient pharmacotherapy rational?]. Barcal M; Slunecko V; Svatek Z Cesk Zdrav; 1971 Jul; 19(7):274-8. PubMed ID: 5556742 [No Abstract] [Full Text] [Related]
19. Developing an effective P & T Committee, Part 2. Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL Hosp Formul; 1985 Oct; 20(10):1071-2, 1078-81, 1086 passim. PubMed ID: 10273830 [TBL] [Abstract][Full Text] [Related]
20. [Detection and prevention of drug-induced lesions. 20 years' experiences in the Drug Committee of the German Medical Society]. Homann G Internist (Berl); 1973 Jan; 14(1):19-24. PubMed ID: 4576792 [No Abstract] [Full Text] [Related] [Next] [New Search]